Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older
NCT06961721Phase 4Not yet recruiting
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- May 2025
- Primary completion
- Jul 2025
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 4, randomised, double-blind trial of zoster vaccine live in herpes zoster (HZ) (2 arms), sponsored by Changchun BCHT Biotechnology Co. Primary endpoint: Immunogenicity at Day 42. Planned start May 2025; status: not yet recruiting.
02
Drugs
zoster vaccine live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06961721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961721.